Updated clinical findings from GEP-NET patients treated with ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE) announced June 17, 2026
Sarclisa SQ approved in the EU as the first anticancer treatment administered via an on-body injector June 17, 2026
First Patient Enrolled in Ph 1b/2 Breast Cancer Study of AK138D1 Combined with Ivonescimab June 17, 2026
Ph 3 trial of Anbenitamab (KN026) + Docetaxel For Injection (Albumin-Bound) (HB1801) For 1L HER2+ve Advanced Breast Cancer Meets Primary Endpoint June 17, 2026
FDA cleared CTA for LILRB4/CD3 targeting TCE bispecific antibody (6MW5311) for the treatment of AML, CMML, and Multiple Myeloma June 17, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each With WELIREG, for Adjuvant Treatment of Certain Patients With Clear Cell RCC June 17, 2026
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares June 17, 2026
Second US Clinical Site Activated and Enrollment Opened for International Ph 2 THIO-101 Expansion Trial June 17, 2026
Update Provided on Safety Profile of LYL273 in R/R Metastatic CRC and Ph 1 Trial Amended to Ph 1/2 Expansion June 17, 2026
Clinical Update Announced from CERTAIN-T Ph 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment June 17, 2026
FAILED TRIAL: Ph 3 LAGOON trial of Zepzelca in patients with 2L SCLC did not meet primary endpoint of OS June 17, 2026
FAILED TRIAL: Ph 2 AMPLIFY-7P trial did not meet the pre-specified primary endpoint of DFS in the ITT adjuvant pancreatic cancer population June 17, 2026
TCX-001 approved by SwissMedic for First-in-Human Ph 1 trial in patients with R/R AML and CLL June 17, 2026
FDA accepted supplemental BLA filing for adjuvant Tecentriq and Tecentriq Hybreza in combination with chemo in stage III dMMR or MSI-H colon cancer and granted Priority Review; PDUFA: 9 October 2026 June 17, 2026
FDA Clearance Received to Complete Enrollment in REGAIN Recurrent GBM Trial and Addition of Two US Clinical Sites June 17, 2026
Alignment with FDA obtained on 80 mg QD as RP3D and on the 2L+ patient population for the ENABLE-2 pivotal trial of ELVN-001 in CML patients June 17, 2026
China NMPA Approves TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer June 17, 2026
Serplulimab Approved by NMPA for Perioperative Gastric Cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy June 17, 2026
